Sphingolipid abnormalities in psychiatric disorders: A missing link in pathology?

Frontiers in Bioscience

Volumn 16, Issue 5, 2011, Pages 1797-1810

  Narayan, Sujatha ^a   Thomas, Elizabeth A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Ceramide; Gene Expression; Glycolipid; Lipid; Lipidomics; Psychiatric; Review

Indexed keywords

VERTEBRATA;

LYSOPHOSPHOLIPID RECEPTOR; SPHINGOLIPID;

ANIMAL; BIPOLAR DISORDER; CELL DIFFERENTIATION; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; METABOLISM; MYELIN SHEATH; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PHYSIOLOGY; PRENATAL DEVELOPMENT; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; BIPOLAR DISORDER; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; DEPRESSIVE DISORDER, MAJOR; HUMANS; LIPID METABOLISM DISORDERS; MEMBRANE MICRODOMAINS; MENTAL DISORDERS; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; OLIGODENDROGLIA; RECEPTORS, LYSOPHOSPHOLIPID; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SPHINGOLIPIDS; SYNAPTIC TRANSMISSION;

EID: 79955047342     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3822     Document Type: Article

References (121)

1. T. Kolter and K. Sandhoff: Sphingolipid metabolism diseases. Biochim Biophys Acta 1758, 2057-79 (2006) (Pubitemid 44879358)
2. R. Navon: Molecular and clinical heterogeneity of adult GM2 gangliosidosis. Dev Neurosci 13, 295-8 (1991)
3. P. I. Rosebush, G. M. MacQueen, J. T. Clarke, J. W. Callahan, P. M. Strasberg, and M. F. Mazurek: Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry 56, 347-53 (1995)
4. N. Zelnik, V. Khazanov, A. Sheinkman, A. M. Karpati, and L. Peleg: Clinical manifestations of psychiatric patients who are carriers of tay-sachs disease. Possible role of psychotropic drugs. Neuropsychobiology 41, 127-31 (2000) (Pubitemid 30172992)
5. B. Colsch, C. Afonso, J. C. Turpin, J. Portoukalian, J. C. Tabet, and N. Baumann: Sulfogalactosylceramides in motor and psycho-cognitive adult metachromatic leukodystrophy: relations between clinical, biochemical analysis and molecular aspects. Biochim Biophys Acta 1780, 434-40 (2008) (Pubitemid 351395306)
6. S. L. Henderson, W. Packman, and S. Packman: Psychosocial aspects of patients with Niemann-Pick disease, type B. Am J Med Genet A 149A, 2430-6 (2009)
7. D. A. Laney, D. J. Gruskin, P. M. Fernhoff, J. F. Cubells, O. Y. Ousley, H. Hipp, and A. J. Mehta: Social-adaptive and psychological functioning of patients affected by Fabry disease. J Inherit Metab Dis (2010)
8. W. Packman, T. Wilson Crosbie, A. Riesner, C. Fairley, and S. Packman: Psychological complications of patients with Gaucher disease. J Inherit Metab Dis 29, 99-105 (2006)
9. L. M. Shulman, N. J. David, and W. J. Weiner: Psychosis as the initial manifestation of adult-onset Niemann-Pick disease type C. Neurology 45, 1739-43 (1995)
10. M. Walterfang, M. Fietz, L. Abel, E. Bowman, R. Mocellin, and D. Velakoulis: Gender dimorphism in siblings with schizophrenia-like psychosis due to Niemann-Pick disease type C. J Inherit Metab Dis (2009)
11. M. Walterfang, M. Fietz, M. Fahey, D. Sullivan, P. Leane, D. I. Lubman, and D. Velakoulis: The neuropsychiatry of Niemann-Pick type C disease in adulthood. J Neuropsychiatry Clin Neurosci 18, 158-70 (2006)
12. P. A. Desplats, C. A. Denny, K. E. Kass, T. Gilmartin, S. R. Head, J. G. Sutcliffe, and T. T. Seyfried: Glycolipid and Ganglioside Metabolism Imbalances In Huntington's Disease Neurobiol Dis (2007)
13. M. O. Grimm, et al.: Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol 7, 1118-23 (2005)
14. P. Katsel, C. Li, and V. Haroutunian: Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? Neurochem Res 32, 845-56 (2007) (Pubitemid 46481322)
15. I. Y. Tamboli, K. Prager, E. Barth, M. Heneka, K. Sandhoff, and J. Walter: Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem 280, 28110-7 (2005) (Pubitemid 41076929)
16. M. M. Rapport: Implications of altered brain ganglioside profiles in amyotrophic lateral sclerosis (ALS). Acta Neurobiol Exp (Wars) 50, 505-13 (1990)
17. G. van Echten-Deckert and T. Herget: Sphingolipid metabolism in neural cells. Biochim Biophys Acta 1758, 1978-94 (2006) (Pubitemid 44879360)
18. T. Wennekes, R. J. van den Berg, R. G. Boot, G. A. van der Marel, H. S. Overkleeft, and J. M. Aerts: Glycosphingolipids - nature, function, and pharmacological modulation. Angew Chem Int Ed Engl 48, 8848-69 (2009)
19. Y. H. Zeidan and Y. A. Hannun: Translational aspects of sphingolipid metabolism. Trends Mol Med 13, 327-36 (2007) (Pubitemid 47126985)
20. Y. A. Hannun: The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 269, 3125-8 (1994) (Pubitemid 24237615)
21. P. P. Ruvolo: Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 47, 383-92 (2003) (Pubitemid 36379200)
22. C. Luberto, J. M. Kraveka, and Y. A. Hannun: Ceramide regulation of apoptosis versus differentiation: a walk on a fine line. Lessons from neurobiology. Neurochem Res 27, 609-17 (2002)
23. S. Spiegel and A. H. Merrill, Jr.: Sphingolipid metabolism and cell growth regulation. FASEB J 10, 1388-97 (1996) (Pubitemid 26347873)
24. Y. A. Hannun: Functions of ceramide in coordinating cellular responses to stress. Science 274, 1855-9 (1996) (Pubitemid 26424756)
25. T. Ariga, W. D. Jarvis, and R. K. Yu: Role of sphingolipid-mediated cell death in neurodegenerative diseases. J Lipid Res 39, 1-16 (1998) (Pubitemid 28063538)
26. A. Jana, E. L. Hogan, and K. Pahan: Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci 278, 5-15 (2009)
27. C. Garcia-Ruiz, A. Colell, M. Mari, A. Morales, and J. C. Fernandez-Checa: Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 272, 11369-77 (1997) (Pubitemid 27184141)
28. E. H. Schuchman: The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. Int J Clin Pharmacol Ther 47 Suppl 1, S48-57 (2009)
29. K. Ogawa-Goto and T. Abe; Gangliosides and glycosphingolipids of peripheral nervous system myelins-a minireview. Neurochem Res 23, 305-10 (1998) (Pubitemid 28109875)
30. W. T. Norton: Isolation and characterization of myelin. Myelin, ed. P. Morell. 1977, New York: Plenum Press. 161-199.
31. M. Eckhardt: The role and metabolism of sulfatide in the nervous system. Mol Neurobiol 37, 93-103 (2008)
32. K. Simons and E. Ikonen: Functional rafts in cell membranes. Nature 387, 569-72 (1997) (Pubitemid 27248754)
33. M. F. Hanzal-Bayer and J. F. Hancock: Lipid rafts and membrane traffic. FEBS Lett 581, 2098-104 (2007) (Pubitemid 46709907)
34. K. Jacobson, O. G. Mouritsen, and R. G. Anderson: Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 9, 7-14 (2007) (Pubitemid 46024188)
35. G. van Meer, D. R. Voelker, and G. W. Feigenson: Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol 9, 112-24 (2008) (Pubitemid 351158912)
36. D. Wheeler, V. V. Bandaru, P. A. Calabresi, A. Nath, and N. J. Haughey: A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 131, 3092-102 (2008)
37. G. M. MacQueen, P. I. Rosebush, and M. F. Mazurek: Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. J Neuropsychiatry Clin Neurosci 10, 10-9 (1998) (Pubitemid 28135118)
38. N. Baumann, J. C. Turpin, M. Lefevre, and B. Colsch: Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships? J Physiol Paris 96, 301-6 (2002) (Pubitemid 36090368)
39. G. D. Cherayil: Estimation of glycolipids in four selected lobes of human brain in neurological diseases. J Neurochem 16, 913-20 (1969)
40. E. G. Brunngraber, L. G. Davis, C. Rieser, and M. V. Reddy: Urinary glycoconjugates in schizophrenic patients. Biol Psychiatry 16, 741-51 (1981) (Pubitemid 11060656)
41. U. Haselhorst, H. Schenk, I. Beyer, R. Uebelhack, E. Franke, and V. Kielstein: Abnormality of gangliosides in erythrocyte membranes of schizophrenic patients. Clin Physiol Biochem 6, 281-4 (1988)
42. A. Schmitt, K. Wilczek, K. Blennow, A. Maras, A. Jatzko, G. Petroianu, D. F. Braus, and W. F. Gattaz: Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry 56, 41-5 (2004) (Pubitemid 38813404)
43. S. Narayan, S. R. Head, T. J. Gilmartin, B. Dean, and E. A. Thomas: Evidence for disruption of sphingolipid metabolism in schizophrenia. J Neurosci Res 87, 278-88 (2009)
44. K. L. Davis, D. G. Stewart, J. I. Friedman, M. Buchsbaum, P. D. Harvey, P. R. Hof, J. Buxbaum, and V. Haroutunian: White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60, 443-56 (2003) (Pubitemid 36539053)
45. M. Kubicki, R. W. McCarley, and M. E. Shenton: Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry 18, 121-34 (2005) (Pubitemid 40824443)
46. E. Schwarz, S. Prabakaran, P. Whitfield, H. Major, F. M. Leweke, D. Koethe, P. McKenna, and S. Bahn: High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7, 4266-77 (2008)
47. J. K. Yao, S. Leonard, and R. D. Reddy: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42, 7-17 (2000) (Pubitemid 30116755)
48. J. Kornhuber, A. Medlin, S. Bleich, V. Jendrossek, A. W. Henkel, J. Wiltfang, and E. Gulbins: High activity of acid sphingomyelinase in major depression. J Neural Transm 112, 1583-90 (2005) (Pubitemid 41504272)
49. J. Kornhuber, M. Reichel, P. Tripal, T. W. Groemer, A. W. Henkel, C. Muhle, and E. Gulbins: The role of ceramide in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 259 Suppl 2, S199-204 (2009)
50. S. Albouz, F. Le Saux, D. Wenger, J. J. Hauw, and N. Baumann: Modifications of sphingomyelin and phosphatidylcholine metabolism by tricyclic antidepressants and phenothiazines. Life Sci 38, 357-63 (1986) (Pubitemid 16169524)
51. M. Kolzer, N. Werth, and K. Sandhoff: Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett 559, 96-8 (2004) (Pubitemid 38186710)
52. S. Marenco and D. R. Weinberger: The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12, 501-27 (2000)
53. J. L. Rapoport, A. M. Addington, S. Frangou, and M. R. Psych: The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10, 434-49 (2005) (Pubitemid 40646432)
54. S. H. Fatemi and T. D. Folsom: The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35, 528-48 (2009)
55. M. Kotani, T. Terashima, and T. Tai: Developmental changes of ganglioside expressions in postnatal rat cerebellar cortex. Brain Res 700, 40-58 (1995)
56. L. Svennerholm, K. Bostrom, P. Fredman, J. E. Mansson, B. Rosengren, and B. M. Rynmark: Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim Biophys Acta 1005, 109-17 (1989) (Pubitemid 19224675)
57. T. Yamashita, R. Wada, T. Sasaki, C. Deng, U. Bierfreund, K. Sandhoff, and R. L. Proia: A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 96, 9142-7 (1999) (Pubitemid 29374721)
58. R. K. Yu, Y. Nakatani, and M. Yanagisawa: The role of glycosphingolipid metabolism in the developing brain. J Lipid Res 50 Suppl, S440-5 (2009)
59. K. A. Sheikh, J. Sun, Y. Liu, H. Kawai, T. O. Crawford, R. L. Proia, J. W. Griffin, and R. L. Schnaar: Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci U S A 96, 7532-7 (1999) (Pubitemid 29299696)
60. R. Jennemann, et al.: Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci U S A 102, 12459-64 (2005) (Pubitemid 41266381)
61. G. Saher, B. Brugger, C. Lappe-Siefke, W. Mobius, R. Tozawa, M. C. Wehr, F. Wieland, S. Ishibashi, and K. A. Nave: High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8, 468-75 (2005) (Pubitemid 41007564)
62. R. Bansal and S. E. Pfeiffer: Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids. Proc Natl Acad Sci U S A 86, 6181-5 (1989) (Pubitemid 19210621)
63. R. Bansal, A. L. Gard, and S. E. Pfeiffer: Stimulation of oligodendrocyte differentiation in culture by growth in the presence of a monoclonal antibody to sulfated glycolipid. J Neurosci Res 21, 260-7 (1988) (Pubitemid 19031351)
64. R. Bansal and S. E. Pfeiffer: Regulation of gene expression in mature oligodendrocytes by the specialized myelin-like membrane environment: antibody perturbation in culture with the monoclonal antibody R-mAb. Glia 12, 173-9 (1994)
65. R. Bansal, S. Winkler, and S. Bheddah: Negative regulation of oligodendrocyte differentiation by galactosphingolipids. J Neurosci 19, 7913-24 (1999) (Pubitemid 30225789)
66. A. Bosio, E. Binczek, and W. Stoffel: Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci U S A 93, 13280-5 (1996) (Pubitemid 26382807)
67. T. Coetzee, N. Fujita, J. Dupree, R. Shi, A. Blight, K. Suzuki, and B. Popko: Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86, 209-19 (1996) (Pubitemid 26286104)
68. J. L. Dupree, T. Coetzee, A. Blight, K. Suzuki, and B. Popko: Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 18, 1642-9 (1998) (Pubitemid 28103072)
69. K. Honke, Y. Hirahara, J. Dupree, K. Suzuki, B. Popko, K. Fukushima, J. Fukushima, T. Nagasawa, N. Yoshida, Y. Wada, and N. Taniguchi: Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc Natl Acad Sci U S A 99, 4227-32 (2002) (Pubitemid 34285968)
70. T. Ishibashi, J. L. Dupree, K. Ikenaka, Y. Hirahara, K. Honke, E. Peles, B. Popko, K. Suzuki, H. Nishino, and H. Baba: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J Neurosci 22, 6507-14 (2002) (Pubitemid 35386407)
71. J. Marcus, S. Honigbaum, S. Shroff, K. Honke, J. Rosenbluth, and J. L. Dupree: Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 53, 372-81 (2006)
72. N. Okamura, M. Stoskopf, F. Hendricks, and Y. Kishimoto: Phylogenetic dichotomy of nerve glycosphingolipids. Proc Natl Acad Sci U S A 82, 6779-82 (1985) (Pubitemid 16209643)
73. N. Okamura, M. Stoskopf, H. Yamaguchi, and Y. Kishimoto: Lipid composition of the nervous system of earthworms (Lumbricus terrestris). J Neurochem 45, 1875-9 (1985) (Pubitemid 16204317)
74. J. M. Boggs, W. Gao, and Y. Hirahara: Myelin glycosphingolipids, galactosylceramide and sulfatide, participate in carbohydrate-carbohydrate interactions between apposed membranes and may form glycosynapses between oligodendrocyte and/or myelin membranes. Biochim Biophys Acta 1780, 445-55 (2008)
75. J. Marcus and B. Popko: Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim Biophys Acta 1573, 406-13 (2002) (Pubitemid 35335451)
76. A. Carlsson and M. Lindqvist: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20, 140-144 (1963)
77. B. Dean: Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. Postgrad Med J 78, 142-8 (2002) (Pubitemid 34229620)
78. A. Becher and R. A. McIlhinney: Consequences of lipid raft association on G-protein-coupled receptor function. Biochem Soc Symp, 151-64 (2005) (Pubitemid 44804743)
79. A. M. Navratil, S. P. Bliss, K. A. Berghorn, J. M. Haughian, T. A. Farmerie, J. K. Graham, C. M. Clay, and M. S. Roberson: Constitutive localization of the gonadotropinreleasing hormone (GnRH) receptor to low density membrane microdomains is necessary for GnRH signaling to ERK. J Biol Chem 278, 31593-602 (2003) (Pubitemid 37048337)
80. Y. Xiang, V. O. Rybin, S. F. Steinberg, and B. Kobilka: Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. J Biol Chem 277, 34280-6 (2002)
81. M. Fallahi-Sichani and J. J. Linderman: Lipid raftmediated regulation of G-protein coupled receptor signaling by ligands which influence receptor dimerization: a computational study. PLoS One 4, e6604 (2009)
82. K. Mirnics, F. A. Middleton, A. Marquez, D. A. Lewis, and P. Levitt: Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67 (2000)
83. K. Mirnics, F. A. Middleton, D. A. Lewis, and P. Levitt: Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci 24, 479-86 (2001) (Pubitemid 32695360)
84. S. Bahn, S. J. Augood, M. Ryan, D. G. Standaert, M. Starkey, and P. C. Emson: Gene expression profiling in the post-mortem human brain - no cause for dismay. J Chem Neuroanat 22, 79-94 (2001) (Pubitemid 32695511)
85. M. B. Knable, E. F. Torrey, M. J. Webster, and J. J. Bartko: Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 55, 651-9 (2001) (Pubitemid 32888384)
86. M. P. Vawter, J. M. Crook, T. M. Hyde, J. E. Kleinman, D. R. Weinberger, K. G. Becker, and W. J. Freed: Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 58, 11-20 (2002) (Pubitemid 35287279)
87. J. Rohrbough and K. Broadie: Lipid regulation of the synaptic vesicle cycle. Nat Rev Neurosci 6, 139-50 (2005) (Pubitemid 40188948)
88. L. H. Chamberlain, R. D. Burgoyne, and G. W. Gould: SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc Natl Acad Sci U S A 98, 5619-24 (2001) (Pubitemid 32435691)
89. F. Darios, et al.: Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. Neuron 62, 683-94 (2009)
90. X. Fan, D. C. Goff, and D. C. Henderson: Inflammation and schizophrenia. Expert Rev Neurother 7, 789-96 (2007) (Pubitemid 47037719)
91. N. Muller, A. M. Myint, and M. J. Schwarz: The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders - relation to drug treatment. Dialogues Clin Neurosci 11, 319-32 (2009)
92. S. Potvin, E. Stip, A. A. Sepehry, A. Gendron, R. Bah, and E. Kouassi: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63, 801-8 (2008) (Pubitemid 351410515)
93. B. I. Goldstein, D. E. Kemp, J. K. Soczynska, and R. S. McIntyre: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70, 1078-90 (2009)
94. D. Arion, T. Unger, D. A. Lewis, P. Levitt, and K. Mirnics: Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 62, 711-21 (2007) (Pubitemid 47374650)
95. S. Narayan, B. Tang, S. R. Head, T. J. Gilmartin, J. G. Sutcliffe, B. Dean, and E. A. Thomas: Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 1239, 235-248 (2008)
96. U. Meyer and J. Feldon: Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology (Berl) 206, 587-602 (2009)
97. N. Muller: COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11, 31-42
98. N. Muller and M. J. Schwarz: COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 14, 1452-65 (2008) (Pubitemid 351982552)
99. M. Riedel, M. Strassnig: M. J. Schwarz, and N. Muller, COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 19, 805-19 (2005) (Pubitemid 43138335)
100. A. Huwiler and J. Pfeilschifter: Lipids as targets for novel anti-inflammatory therapies. Pharmacol Ther 124, 96-112 (2009)
101. A. Huwiler, B. Johansen, A. Skarstad, and J. Pfeilschifter: Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J 15, 7-9 (2001)
102. E. Klapisz, J. Masliah, G. Bereziat, C. Wolf, and K. S. Koumanov: Sphingolipids and cholesterol modulate membrane susceptibility to cytosolic phospholipase A(2). J Lipid Res 41, 1680-8 (2000)
103. B. J. Pettus, A. Bielawska, P. Subramanian, D. S. Wijesinghe, M. Maceyka, C. C. Leslie, J. H. Evans, J. Freiberg, P. Roddy, Y. A. Hannun, and C. E. Chalfant: Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 279, 11320-6 (2004) (Pubitemid 38401629)
104. R. V. Stahelin, P. Subramanian, M. Vora, W. Cho, and C. E. Chalfant: Ceramide-1-phosphate binds group IVA cytosolic phospholipase a2 via a novel site in the C2 domain. J Biol Chem 282, 20467-74 (2007) (Pubitemid 47100015)
105. B. J. Pettus, A. Bielawska, S. Spiegel, P. Roddy, Y. A. Hannun, and C. E. Chalfant: Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. J Biol Chem 278, 38206-13 (2003) (Pubitemid 37221709)
106. L. R. Ballou, S. C. Barker, A. E. Postlethwaite, and A. H. Kang: Sphingosine potentiates IL-1-mediated prostaglandin E2 production in human fibroblasts. J Immunol 145, 4245-51 (1990)
107. L. R. Ballou, C. P. Chao, M. A. Holness, S. C. Barker, and R. Raghow: Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 267, 20044-50 (1992)
108. M. J. Lee, J. R. Van Brocklyn, S. Thangada, C. H. Liu, A. R. Hand, R. Menzeleev, S. Spiegel, and T. Hla: Sphingosine-1-phosphate as a ligand for the G proteincoupled receptor EDG-1. Science 279, 1552-5 (1998) (Pubitemid 28217081)
109. S. Spiegel and S. Milstien: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4, 397-407 (2003) (Pubitemid 36565571)
110. N. Young and J. R. Van Brocklyn: Signal transduction of sphingosine-1-phosphate G proteincoupled receptors. ScientificWorldJournal 6, 946-66 (2006) (Pubitemid 44252720)
111. B. J. Pettus, J. Bielawski, A. M. Porcelli, D. L. Reames, K. R. Johnson, J. Morrow, C. E. Chalfant, L. M. Obeid, and Y. A. Hannun: The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 17, 1411-21 (2003) (Pubitemid 36939148)
112. L. Y. Chen, G. Woszczek, S. Nagineni, C. Logun, and J. H. Shelhamer: Cytosolic phospholipase A2alpha activation induced by S1P is mediated by the S1P3 receptor in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 295, L326-35 (2008)
113. A. Damirin, H. Tomura, M. Komachi, M. Tobo, K. Sato, C. Mogi, H. Nochi, K. Tamoto, and F. Okajima: Sphingosine 1-phosphate receptors mediate the lipidinduced cAMP accumulation through cyclooxygenase2/prostaglandin I2 pathway in human coronary artery smooth muscle cells. Mol Pharmacol 67, 1177-85 (2005) (Pubitemid 40410417)
114. Phospholipid Spectrum Disorders in Psychiatry and Neurology. 2nd ed, ed. M. Peet, I. Glen, and D.F. Horrobin. 2003, Lancashire: Marius Press.
115. D. F. Horrobin: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30, 193-208 (1998) (Pubitemid 28189552)
116. D. F. Horrobin and C. N. Bennet: New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins, Leukotrienes and Essential Fatty acids 60, 141-167 (1999) (Pubitemid 29213885)
117. W. S. Fenton, J. Hibbeln, and M. Knable: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47, 8-21 (2000) (Pubitemid 30016075)
118. J. K. Yao, D. P. van Kammen, and J. A. Gurklis: Abnormal incorporation of arachidonic acid into latelets of drug-free patients with schizophrenia. Psychiatry Res 60, 11-21 (1996) (Pubitemid 26076966)
119. G. F. Nixon: Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol 158, 982-93 (2009)
120. D. N. Black, K. H. Taber, and R. A. Hurley: Metachromatic leukodystrophy: a model for the study of psychosis. J Neuropsychiatry Clin Neurosci 15, 289-93 (2003) (Pubitemid 36999371)
121. R. Navon, Z. Argov, and A. Frisch: Hexosaminidase A deficiency in adults. Am J Med Genet 24, 179-96 (1986) (Pubitemid 16033555)